menu
    • menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Nepafenac","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17999999999999999,"dosageForm":"Suspension\/Drops","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow"},{"orgOrder":0,"company":"Harrow","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Nepafenac","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Suspension\/Drops","sponsorNew":"Harrow \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Novartis"}]

    Find Clinical Drug Pipeline Developments & Deals for Nepafenac

    Menu

    Nepafenac

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Harrow

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $130.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Wil...

                            Details : Ilevro (nepafenac) is a non-steroidal anti-inflammatory drug (NSAID). It stops the body from making chemicals that cause inflammation, which helps lessen pain and swelling in the eye due to surgery.

                            Brand Name : Ilevro

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 23, 2023

                            Lead Product(s) : Nepafenac

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $130.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Harrow

                            Deal Size : $175.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to Ilevro®, Nevanac®, Vigamox®, Maxidex®, An...

                            Details : Ilevro® (nepafenac ophthalmic suspension) is a 0.3%, a non-steroidal, anti-inflammatory eye drop indicated for pain and inflammation associated with cataract surgery.

                            Brand Name : Ilevro

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 14, 2022

                            Lead Product(s) : Nepafenac

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Harrow

                            Deal Size : $175.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth